Michel Orsinger proposed to become Chairman

7 April 2011, 06:45 CET

At the company’s annual general meeting in March 2012, the Board of Directors of Nobel Biocare Holding Ltd will propose that shareholders elect Michel Orsinger, President & CEO of Synthes, to the Board, after which he will be appointed Chairman of the Board of Nobel Biocare. The current Chairman, Heino von Prondzynski, has requested that the Board accept his resignation from the chairmanship and the Board. The appointment of Michel Orsinger as new Chairman will take place with the support of Heino von Prondzynski and at the unanimous approval of the Board of Directors.

Michel Orsinger has been active at Synthes since 2004, initially as COO and as of 2007 as the company’s President and CEO. Under his leadership, Synthes has sustainably strengthened its position as a globally leading orthopedics and medical technology company. Michel Orsinger has many years of experience in the healthcare industry and an outstanding reputation in the medtech field. The Board of Directors would like to thank Heino von Prondzynski for his valuable contribution to the development of Nobel Biocare, as well as for his successful installation and indoctrination of the company’s new CEO, Richard Laube. Until the 2012 annual general meeting, the previous Vice-Chairman of the Board, Dr. Rolf Watter, will chair the supervisory body on an ad interim basis.

Due to his commitments at Synthes, Michel Orsinger will only become available as of early 2012. With immediate effect, however, he will be attending board meetings as a guest. Consequently, he is at the board’s disposal already today and can work his way into his new task in a timely manner.

“I am looking forward to joining the Board of Nobel Biocare Holding Ltd provided I am elected by the shareholders at the AGM in spring 2012,” said Michel Orsinger. “I know the company since my time as a former Board member and have always been following its development with great interest. Together with Richard Laube, we will further intensify our efforts on innovation, customers and employees.”

"I came to my decision to step down from the Board of Directors after a long period of reflection and only after I had time to work with Richard Laube ensuring that Nobel Biocare is on the right path," said Heino von Prondzynski. "I am pleased that, in Michel Orsinger, a highly qualified professional and outstanding personality has been found to be my successor. He will bring excellent industry expertise and people skills to the Board of Directors. Now that Nobel Biocare is on track, it is my intention to contribute to the unity and strength of the company's senior management. I wish great success to Nobel Biocare and to my successor."

"Michel Orsinger has an outstanding grasp of the medtech and dental industries," said Chairman ad interim, Rolf Watter. "As a guest of the Board he will be able to contribute his vast knowledge and experience with immediate effect. The whole board welcomes him warmly. I would like to thank Heino von Prondzynski for his tremendous dedication and valuable contribution to this development. The Board is also very pleased with the work of CEO Richard Laube to date. The Board of Directors and Executive Committee will refrain from commenting further until the presentation of the half year results on 12 August 2011."

“I regret but understand Heino von Prondzynski’s decision. Since joining the company, I was impressed by how engaged he was in the business, and by how he shared knowledge for the business”, said Richard Laube, CEO of Nobel Biocare. “Michel Orsinger is undoubtedly an eminent expert in this industry. I am confident that our company will greatly benefit from his nomination. I know Michel well and am very much looking forward to working with him again.”

Media contact

Name: Nicolas Weidmann (Senior Vice President Corporate Communications & Global Marketing)
Tel: +41 43 211 42 80; +41 79 372 29 81
E-mail: nicolas.weidmann@nobelbiocare.com

Investor contact

Name: Süha Demokan (Vice President Investor & Corporate Relations)
Tel: +41 43 211 42 30; +41 79 430 81 46
E-mail: suha.demokan@nobelbiocare.com

Nobel Biocare (NOBN, SIX Swiss Exchange) is a world leader in the field of innovative implant-based dental restorations. The company’s portfolio offers solutions from single tooth to fully edentulous indications with dental implant systems (including key brands NobelActive®, Brånemark System® and NobelReplace®), a comprehensive range of high-precision individualized prosthetics and CAD/CAM systems (NobelProcera®), diagnostics, treatment planning and guided surgery solutions (NobelClinician™ and NobelGuide®) and biomaterials (Creos™). Nobel Biocare supports its customers through all phases of professional development, offering world-class training and education along with practice support and patient information materials. The company is headquartered in Zurich, Switzerland, currently employs approximately 2,500 employees worldwide and recorded revenue of EUR 566.8 million in 2013. Production takes place at seven sites located in Canada, Israel, Japan, Sweden, and the United States. Products and services are available in over 80 countries through subsidiaries and distributors.

This media release contains forward-looking statements based on beliefs of Nobel Biocare’s management. When used in this media release, words such as “anticipate”, “believe”, “estimate”, “expect”, “intend”, “plan” and “project” are intended to identify forward-looking statements. They may involve risks and uncertainties, including technological advances in the medical field, product demand and market acceptance, the effect of economic conditions, the impact of competitive products and pricing, foreign currency exchange rates and other risks. These forward-looking statements reflect the views of Nobel Biocare as of the date made with respect to future events and are subject to risks and uncertainties. All of these forward-looking statements are based on estimates and assumptions made by management of the company and are believed to be reasonable, though are inherently uncertain and difficult to predict. Actual results or experience could differ materially from the forward-looking statements. Nobel Biocare disclaims any intention or obligation to update these forward-looking statements.

Media contact

Süha Demokan

Süha Demokan

Vice President Investor & Corporate Relations

Nobel Biocare Management AG 
P.O. Box
CH - 8058 Zurich-Airport

+41 43 211 42 30

+41 79 430 81 46

+41 43 211 58 11

Give us your feedback!

Summarize your comments